Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.

ABSTRACT:

Background

Bladder cancer is the 10th most common cancer globally, with a growing incidence in Japan. Evaluation of molecular, genetic, and cellular biomarkers that predict treatment response and prognosis in patients with metastatic urothelial carcinoma (mUC) may help optimize sequential treatment strategies with chemotherapy and immune checkpoint inhibitors (ICIs).

Methods

This multicenter, retrospective cohort study, evaluated programmed death-ligand 1 (PD-L1) expression, tumor mutational burden (TMB), and cancer-immune phenotype as predictive prognostic biomarkers following first-/second-line treatment in Japanese adult patients with mUC. The primary endpoint was prevalence of PD-L1 expression. Secondary endpoints were TMB, overall survival (OS), and progression-free sur

SUBMITTER: Nishiyama H 

PROVIDER: S-EPMC10543076 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature